Citat:
Blandmissbruk ökar risken för cancer. Det är långt troligare än något du blivit förskriven.
Källa på det tack.
Citat:
Provet de har tagit är helt ospecifikt och behöver inte betyda att du har cancer. Det används framförallt för att kontrollera om man fått återfall efter man behandlats för cancer.
Fel, läs här:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576775/
Published online 2015 Apr 15.
Gastric cancer ranks third in terms of mortality rates.
In gastric cancer, the most used tumor markers are: CA 72-4, carcinoembryonic antigen (CEA) and cancer-related antigen 19-9 (CA 19-9).
Less than 20% of the newly diagnosed cases are stage I or II, the rest of them already being regional or distant metastases, in which case the chances of recovery are close to zero and the average survival rate is of 6 months to 1 year.
Chen’s meta-analysis, which included 33 published studies, found an overall accuracy of 77% for CA 72-4, much higher than the accuracy of the other markers under scrutiny.
CA 19-9 appears to be an independent predictive factor in the case of metastatic patients.
In gastric cancer, the sensitivity of CEA is of approximately 30%, by comparison with colorectal cancer, in which its sensitivity is of 74%.
The sensitivity of CA 19-9 in gastric cancer is higher than that of CEA, being of 42%. By contrast, in colorectal cancer, CA 19-9 is less effective, its sensitivity being of only 26%.
If cases are assessed by associating the two markers, sensitivity increases to 58%. CEA appears to be the marker to be preferred in colorectal cancer, whereas CA 19-9 seems to be more sensitive in gastric cancer.
A Japanese meta-analysis has studied the role of tumor markers in gastric cancer. Over 4900 articles were selected from the available publications. Out of these articles, only 187 had references to CEA and CA 19-9 and only 19 to all three markers. The overall true positive rate was of 21% for CEA, of 27.8% for CA 19-9 and of 30% for CA 72-4.
CEA appears to be the marker with the highest sensitivity both in early gastric cancer and in more advanced stages of the disease: 40% and 100% respectively, by comparison with CA 19-9 (5.6% and 68.2%) and CA 72-4 (2.8% and 51.3%).
Monitoring patients using tumor markers allows the early diagnosis of metastases or of relapse, despite the fact that the ESMO guidelines underline that early diagnosis does not improve survival.